ReviewBrain and behavior2017
The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis.
Review in Brain and behavior, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Interferon-Beta Injection in Multiple Sclerosis Patients Related to the Induction of Headache and Flu-Like Pain Symptoms: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.Current neuropharmacology · 2022Pooled it
- Neural Stem Cells in Multiple Sclerosis: A Comprehensive Review of Preclinical and Clinical Evidence for CNS Repair and Translational Hurdles.Applied biochemistry and biotechnology · 2026Review
- Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis.Non-coding RNA research · 2025Article
- Viruses and neurodegeneration: a growing concern.Journal of translational medicine · 2025Review
- Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications.European journal of medical research · 2024Review
- Emerging strategies for nanomedicine in autoimmunity.Advanced drug delivery reviews · 2024Review
- Controlling the Quality of Nanodrugs According to Their New Property-Radiothermal Emission.Pharmaceutics · 2024Article
- Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges.Journal of clinical medicine · 2023Review
- In Silico Drug Repurposing in Multiple Sclerosis Using scRNA-Seq Data.International journal of molecular sciences · 2023Article
- Interaction of the viral infectious agents in the development and exacerbation of the multiple sclerosis.Le infezioni in medicina · 2023Review
- Does multiple sclerosis have a zoonotic origin? Correlations with lymphocytic choriomeningitis virus infection.Frontiers in immunology · 2023Article
- Sex-Specific Environmental Impacts on Initiation and Progression of Multiple Sclerosis.Frontiers in neurology · 2022Review
- Divergent complement system activation in two clinically distinct murine models of multiple sclerosis.Frontiers in immunology · 2022Article
- Review
- Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Review
- Review
- Optimized Protocol for Subcutaneous Implantation of Encapsulated Cells Device and Evaluation of Biocompatibility.Frontiers in bioengineering and biotechnology · 2021Article
- The Role of Natural Killer Cells in Autoimmune Diseases.Frontiers in immunology · 2021Review
- An engineered 4-1BBL fusion protein with "activity on demand".Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of interferon beta therapies more than 20 years ago marked a milestone in the treatment of relapsing-remitting multiple sclerosis (RRMS) with a significant impact on the approach to modern multiple sclerosis (MS) care. Key learnings and perspectives from the early days of disease modifying therapies in MS have improved the knowledge base of MS, need for treatment, and patient care. The continuous development of interferons over the past two decades outlines a journey with increased understanding of the pharmacodynamics and pharmacokinetic mechanisms of interferons, leading to innovative formulations with an improved benefit/risk profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.